SMAD2 and non-small cell lung carcinoma: These findings identified the ratio SMAD3/SMAD2 (at RNA or protein level) as a useful functional biomarker for myCAFs in NSCLC (Fig. 2D), since it is indicative of many histotype‐dependent alterations reported in lung CAFs [54, 65, 93] (Fig. 2E).